Upgrade to SI Premium - Free Trial

Ardelyx (ARDX): FDA Will Have "Difficult Time Justifying Another Rejection" - Piper Sandler Bullish Post AdCom Vote

November 17, 2022 6:39 AM
Piper Sandler analyst Christopher Raymond upgraded Ardelyx, Inc (NASDAQ: ARDX) from Neutral to Overweight with a price target of $8.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments Hot Upgrades Upgrades

Next Articles